GCIWhen a CEO stepping down is probably a positive
A CEO stepping down is not normally regarded as a positive news event but when the incoming CEO has more experience, in relevant sectors to the business, it could just be.
The share price of the dropped by 11% when it’s CEO recently stepped down but the new CEO, Dr Debra Barker, has worked at Novartis, Roche, GSK and most recently in C-Suite roles at Polyphor and Polyneuron. At Novartis Dr Barker held several senior roles including Head of Development for Anti-Infectives, Immunology and Transplantation. Dr Barker was also the medical lead for Swiss based anti-infective specialist Polyphor's highly successful IPO on the SIX Swiss Exchange.
Also last week the company announced they were attending a major international biopharma conference looking at the potential partnering opportunities. They have previously stated a partnering deal on their 2nd asset will happen this year.
The resignation of the Neil Clark ,the previous CEO, has had no effect on the broker targets for the company. Three separate brokers have share price targets that average 285p, on this company, which is currently 850% higher than the current share price.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.